Trials / Active Not Recruiting
Active Not RecruitingNCT04148430
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra | 100mg subcutaneous |
Timeline
- Start date
- 2019-10-30
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2019-11-01
- Last updated
- 2025-11-05
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04148430. Inclusion in this directory is not an endorsement.